<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028764</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-1601-002</org_study_id>
    <nct_id>NCT05028764</nct_id>
  </id_info>
  <brief_title>Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers</brief_title>
  <official_title>A Study to Determine the Range of Tissue Frataxin Concentrations and Other Potential Biomarkers for Friedreich's Ataxia in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larimar Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinilabs, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larimar Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine range of tissue frataxin (FXN) concentrations, specific ribonucleic acids, other&#xD;
      proteins and specialized lipids in the buccal cells, blood, and skin cells of normal healthy&#xD;
      volunteers without Friedreich's ataxia (FRDA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To examine the range of tissue frataxin (FXN) concentrations in the buccal&#xD;
      cells, blood, and skin cells of normal healthy volunteers without FRDA.&#xD;
&#xD;
      Secondary Objective: To examine the range of specific ribonucleic acids (RNAs), other&#xD;
      proteins, and specialized lipids in the buccal cells, blood, and skin cells of normal healthy&#xD;
      volunteers without FRDA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Examine tissue frataxin concentrations in buccal cells, blood and skin cells</measure>
    <time_frame>1 day</time_frame>
    <description>Range of tissue frataxin levels in buccal cells, blood and skin cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine specific ribonucleic acids (RNAs), other proteins, and specialized lipids in buccal cells and blood</measure>
    <time_frame>1 day</time_frame>
    <description>Range of specific ribonucleic acids (RNAs), other proteins, and specialized lipids in buccal cells and blood</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Friedreich Ataxia</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>18 to 30 years of age group</arm_group_label>
    <description>Consisting of at least 13 males and 13 females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>31 to 50 years of age group</arm_group_label>
    <description>Consisting of at least 13 males and 13 females</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Buccal Swabs, Blood Draws and Skin Punch Biopsy</intervention_name>
    <description>Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers</description>
    <arm_group_label>18 to 30 years of age group</arm_group_label>
    <arm_group_label>31 to 50 years of age group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal cells and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a healthy male or female,18-50 years of age&#xD;
&#xD;
          2. Subject has a body mass index (BMI) ≥18.0 and ≤32.0 as of the screening visit.&#xD;
&#xD;
          3. Subject is racially Caucasian, Asian, Native Hawaiian, or Native American.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to&#xD;
             the Day 1 (assessment) visit.&#xD;
&#xD;
          2. Subject has a chronic condition that requires ongoing prescription drug treatment.&#xD;
&#xD;
          3. Subject use of any statin medications within 3 months before the Day 1 (assessment)&#xD;
             visit.&#xD;
&#xD;
          4. Subject use of any lipid-lowering agents, other than statins, within 6 weeks before&#xD;
             the Day 1 (assessments) visit.&#xD;
&#xD;
          5. Subject is racially black or African American.&#xD;
&#xD;
          6. Pregnant or breast-feeding female subjects.&#xD;
&#xD;
          7. Subject has a known history of drug or alcohol abuse or current suspected drug or&#xD;
             alcohol abuse.&#xD;
&#xD;
          8. Subject is positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV),&#xD;
             hepatitis B surface antigen (HBsAg), or hepatitis A virus (HAV).&#xD;
&#xD;
          9. Subject has any condition, disease, or situation, that in the opinion of the principal&#xD;
             investigator (PI), could confound the results of the study or put the subject at undue&#xD;
             risk, making participation inadvisable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Shenouda, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Tiernan</last_name>
    <phone>212-994-4150</phone>
    <email>dtiernan@clinilabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Tiernan</last_name>
      <phone>212-994-4150</phone>
      <email>dtiernan@clinilabs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010 Oct-Nov;101(2-3):238-45. doi: 10.1016/j.ymgme.2010.07.001. Epub 2010 Jul 8.</citation>
    <PMID>20675166</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

